TSTickerStarGet alerts

EyePoint reports Q3 2026 loss of ($1.07) per share; strategic prioritization includes 53% workforce reduction and $30M annualized savings

EyePoint reported Q3 2026 total revenue of $0.8 million compared to $1.0 million in Q3 2025, with net loss of ($95.6) million or ($1.07) per share versus a net loss of ($59.7) million or ($0.85) per share in the prior year period. Operating expenses increased to $97.6 million from $63.0 million, driven by ongoing DURAVYU Phase 3 clinical trials for wet AMD and DME. Cash, cash equivalents, and marketable securities totaled $118 million as of September 30, 2026, down from $306 million at December 31, 2025. The com...

Share this story

Guidance updates

DME Phase 3 topline data timingQ4 2027
Early Q4 2027Prior Q4 2027 | maintained | Specified as early Q4 2027

Key takeaways

  • Revenue: Q3 2026 revenue of $0.8 million decreased from $1.0 million in Q3 2025 due to lower license, collaboration, and royalty income

  • Net loss: ($95.6) million or ($1.07) per share compared to ($59.7) million or ($0.85) per share in Q3 2025

  • Cash position: $118 million as of September 30, 2026, down from $306 million at December 31, 2025; expects to fund operations into late Q3 2027

  • Strategic prioritization: Following Phase 3 LUCIA results, board approved approximately 53% workforce reduction expected to generate $30 million in annualized savings

  • DME program: Phase 3 COMO and CAPRI trials fully enrolled with over 550 patients; topline data expected early Q4 2027

  • Wet AMD program: Phase 3 LUGANO and LUCIA trials did not meet primary endpoint but achieved key secondary endpoints including 38-42% reduction in treatment burden; wet AMD program to be concluded

  • Post-quarter financing: $10 million raised via at-the-market equity facility subsequent to quarter-end

Key metrics

Total revenueQ3 2026
$0.8 milliondecreased from $1.0 million
Product sales, netQ3 2026
$528 thousanddecreased from $582 thousand
License and collaboration agreementsQ3 2026
$49 thousanddecreased from $150 thousand
Royalty incomeQ3 2026
$179 thousanddecreased from $234 thousand
Net lossQ3 2026
($95.6) millionwider loss from ($59.7) million
Net loss per share (basic and diluted)Q3 2026
($1.07)wider loss from ($0.85)
Loss from operationsQ3 2026
($96.9) millionwider loss from ($62.0) million
Operating expensesQ3 2026
$97.6 millionincreased from $63.0 million

Disclosure changes

  • Strategic prioritization and workforce reduction

    Following the LUCIA results, the Board of Directors approved a strategic prioritization designed to extend financial resources and focus on the late-stage DME program. The resulting approximately 53% workforce reduction, as well as associated operational adjustments, are expected to generate an estimated annualized savings of approximately $30 million.

    Significant cost reduction initiative to extend cash runway amid clinical development spending
  • Wet AMD program conclusion

    The company will conclude the wet AMD program before completion of the full second year of the Phase 3 studies for both LUGANO and LUCIA, while also allowing additional patients to complete year two to support the necessary safety database for a potential new drug application for DME.

    Company is pivoting resources away from wet AMD to focus on DME program after Phase 3 trials missed primary endpoint
  • At-the-market equity offering

    The company raised an additional $10 million subsequent to quarter-end pursuant to its at-the-market equity facility.

    Company accessed ATM facility to extend cash runway

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow EYPT in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert